---
document_datetime: 2023-09-21 22:02:07
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/pioglitazone-actavis-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: pioglitazone-actavis-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 9.8648075
conversion_datetime: 2025-12-21 22:44:46.297188
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Pioglitazone Actavis

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued² / amended on   | Product Information affected3   | Summary   |
|----------------------|------------------------------------------------------------------------|-------------------------------------|--------------------------------------------|---------------------------------|-----------|
| IG/1612              | A.1 - Administrative change - Change in the name and/oraddressoftheMAH | 31/05/2023                          |                                            | SmPC, Labelling and PL          |           |
| IAIN/0016/G          | Thiswas an applicationfor a groupofvariations.                         | 26/04/2021                          | 24/06/2021                                 | SmPC, Annex II and PL           |           |

1 Notifications are issued for type I variations and Article61(3)notifications(unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedforallotherprocedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

2A Commissiondecision(CD)isissuedforprocedures that affecttheterms ofthemarketing authorisation(e.g.summaryofproduct characteristics,annexII,labelling,packageleaflet).The CD is issued within twomonths of the opinion for variations falling under the scope of Article23.1a(a) of Regulation(EU) No.712/2012, or within one yearfor otherprocedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| A.7-Administrativechange-Deletionof A.5.a-Administrative change -Change in the name and/oraddressof amanufacturer/importer responsible for batch release                                                                                                                                                                                                                                                                                                                                                            |            |            |          | manufacturing sites                             |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-------------------------------------------------|
| This was an applicationfor a group of variations. B.I.b.1.h-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Additionor replacement(excl.Biol.orimmunol.substance)ofa specification parameter as a result of a safety or quality issue B.II1.1.a.2-Submission of a new/updated or deletion ofPh.Eur.Certificateof Suitability to the relevantPh.Eur.Monograph-Updated certificate                                                                              | 12/08/2020 | n/a        |          | IB/0015/G from an already approved manufacturer |
| This was an application for a variation following a worksharingprocedure according toArticle20of CommissionRegulation(EC)No1234/2008. TheRMPwasupdatedtotheRMPtemplaterev2as per GVP module V rev 2, and the existing additional riskminimisationmeasures(educationalpackforthe healthcareprofessionalscontainingaprescriber guide)wereremovedbothfromtheRMPandtheir key elementsfrom theAnnexIIDofthePI,in line with the originator product for pioglitazone. In addition, standard wording was reinstated for the | 11/06/2020 | 24/06/2021 | Annex II | WS/1791                                         |

<div style=\"page-break-after: always\"></div>

|             | PSURsubmissionrequirementwith areference to the updates included in the EURDlist. C.I.11.b-Introduction of,or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s)whichrequiretobefurthersubstantiated bynewadditional datatobesubmittedby theMAH wheresignificantassessment isrequired   |            |            |                  |                                                                                                                                                                                                                                                                 |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0013/G | Thiswasanapplicationforagroupofvariations. A.7-Administrativechange-Deletion of manufacturing sites B.II1.1.a.3-Submission of a new/updated or deletion ofPh.Eur.CertificateofSuitability to the relevantPh.Eur.Monograph-New certificatefrom a newmanufacturer(replacementoraddition)                                                                          | 07/01/2020 | n/a        |                  |                                                                                                                                                                                                                                                                 |
| N/0012      | Minorchangeinlabellingorpackageleafletnot connected with the SPC(Art.61.3 Notification)                                                                                                                                                                                                                                                                         | 20/03/2018 | 24/06/2021 | PL               |                                                                                                                                                                                                                                                                 |
| N/0011      | Minorchangeinlabellingorpackageleafletnot connectedwiththeSPC(Art.61.3Notification)                                                                                                                                                                                                                                                                             | 09/08/2017 | 24/06/2021 | Labelling and PL |                                                                                                                                                                                                                                                                 |
| R/0009      | Renewal of themarketing authorisation.                                                                                                                                                                                                                                                                                                                          | 15/09/2016 | 11/11/2016 |                  | Based on the review of data on quality, safety and efficacy, theCHMPconsidered thatthebenefit-riskbalanceof PioglitazoneActavisintheapprovedindicationremains favourableandthereforerecommendedtherenewalofthe marketing authorisation with unlimited validity. |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IB/0010/G   | This was an application for a group of variations. C.I.2.a-Change in the SPC,Labelling or PL of a   | 30/09/2016   | 14/11/2016   | SmPC, Labelling and PL   |                     |
|-------------|-----------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|---------------------|
| IA/0008     | A.7-Administrativechange-Deletionof                                                                 | 03/06/2016   | n/a          |                          | manufacturing sites |
| IAIN/0007/G | This was an application for a group of variations.                                                  | 03/03/2016   | n/a          |                          |                     |

<div style=\"page-break-after: always\"></div>

| A.7-Administrative change-Deletion of manufacturing sites B.III.1.a.1-Submission of a new/updated or deletion ofPh.Eur.CertificateofSuitability to the relevantPh.Eur.Monograph-New certificatefrom analreadyapprovedmanufacturer         |            |            |             |           |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------|
| Minorchangeinlabellingorpackageleafletnot connected with the SPC(Art.61.3 Notification)                                                                                                                                                   | 11/12/2015 | 11/11/2016 | PL          | N/0006    |
| C.I.8.a-Introductionofor changestoasummaryof Pharmacovigilancesystem-ChangesinQPPV (including contact details)and/or changesin the PSMFlocation                                                                                           | 20/07/2015 | n/a        |             | IAIN/0005 |
| Minorchangeinlabellingorpackageleafletnot connectedwiththeSPC(Art.61.3Notification)                                                                                                                                                       | 18/02/2015 | 11/11/2016 | PL          | N/0004    |
| C.1.11.z-Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation，includingtheRMp-Othervariation                                                                                                     | 06/03/2014 | n/a        |             | IB/0003   |
| C.I.2.a-Change in the SPC,Labelling orPL of a generic/hybrid/biosimilar products following assessmentofthesamechangeforthereference product - Implementation of change(s) for which NO newadditionaldataisrequiredtobesubmittedby the MAH | 12/12/2013 | 11/11/2014 | SmPC and PL | IB/0002   |
| C.I.2.a-Change in the SPC,Labelling or PL of a                                                                                                                                                                                            | 08/11/2013 | 11/11/2014 | SmPC, Annex | IB/0001   |

<div style=\"page-break-after: always\"></div>

| generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional dataisrequired tobesubmitted by the MAH   | II, Labelling and PL   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|